Zongertinib (BI1810631), an irreversible HER2 TKI spares EGFR signaling and improves therapeutic response in preclinical models and patients with HER2-driven cancers

被引：0
|
作者：
Neumueller, R. [1 ]
Wilding, B. [1 ]
Augsten, M. [1 ]
Baum, A. [1 ]
Chylinski, K. [1 ]
Waizenegger, I. [1 ]
Woelflingseder, L. [1 ]
Solca, F. [1 ]
Kraut, N. [1 ]
机构：
[1] Boehringer Ingelheim RCV, Oncol Res, Vienna, Austria
来源：
EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷
关键词：
D O I：
10.1016/j.ejca.2024.114659
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PB124
引用
收藏
页码：S56 / S56
页数：1
相关论文
共 29 条
  • [21] AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models
    Zhaomei Mu
    Teresa Klinowska
    Xiaoshen Dong
    Emily Foster
    Chris Womack
    Sandra V Fernandez
    Massimo Cristofanilli
    Journal of Experimental & Clinical Cancer Research, 33
  • [22] AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models
    Mu, Zhaomei
    Klinowska, Teresa
    Dong, Xiaoshen
    Foster, Emily
    Womack, Chris
    Fernandez, Sandra V.
    Cristofanilli, Massimo
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2014, 33
  • [23] Use of BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor (TKI), to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastuzumab
    Hickish, T.
    Wheatley, D.
    Lin, N.
    Carey, L.
    Houston, S.
    Mendelson, D.
    Solca, F.
    Uttenreuther-Fischer, M.
    Jones, H.
    Winer, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [24] Phase Ia/Ib trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor (TKI), in patients (pts) with HER2 aberration-positive solid tumors: Updated Phase Ia data from Beamion LUNG-1, including progression-free survival (PFS) data
    Heymach, John
    Opdam, Frans
    Barve, Minal A.
    Tu, Hai-Yan
    Wu, Yi-Long
    Berz, David
    Rohrbacher, Maren
    Sadrolhefazi, Behbood
    Serra, Josep
    Yoh, Kiyotaka
    Yamamoto, Noboru
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] Use of BIBW 2992, a novel irreversible EGFR/HER2 TKI, to induce regression in patients with adenocarcinoma of the lung and activating EGFR mutations: Preliminary results of a single-arm phase II clinical trial
    Yang, C.
    Shih, J.
    Chao, T.
    Tsai, C.
    Yu, C.
    Yang, P.
    Streit, M.
    Shahidi, M.
    Miller, V. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [26] A phase 3 randomized controlled trial of zongertinib (BI 1810631) compared with standard of care in patients with locally advanced or metastatic nonsquamous non-small cell lung cancer harboring HER2 tyrosine kinase domain mutations: Beamion LUNG-2
    Wu, Yi-Long
    Johnson, Melissa
    Soo, Ross
    Baktash, Navid
    Maier, Daniela
    Eigenbrod-Giese, Sabina
    Yoshida, Tatsuya
    CANCER RESEARCH, 2024, 84 (07)
  • [27] A phase II study of BIBW 2992, a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor (TKI), in patients with adenocarcinoma of the lung and activating EGFR mutations after failure of one line of chemotherapy (LUX-Lung 2)
    Shih, J.
    Yang, C.
    Su, W.
    Hsia, T.
    Tsai, C.
    Chen, Y.
    Chang, H.
    Terlizzi, E.
    Shahidi, M.
    Miller, V. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [28] Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care (SoC) in patients with locally advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD) mutations
    Johnson, Melissa Lynne
    Soo, Ross A.
    Wu, Yi-Long
    Baktash, Navid
    Maier, Daniela
    Eigenbrod-Giese, Sabina
    Yoshida, Tatsuya
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] Beamion BCGC-1: A phase Ib/II trial of the HER2-selective tyrosine kinase inhibitor (TKI) zongertinib (BI 1810631) + trastuzumab deruxtecan (T-DXd) or trastuzumab emtansine (T-DM1) for patients with metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC).
    Nakayama, Izuma
    Berz, David
    Yazgili, Sila Aykut
    Erzen, Damijan
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS509 - TPS509
123